by VARALAKSHMI PULUGURTHA
Targeted News Service
WASHINGTON, July 17 -- The U.S. National Institutes of Health has announced that it expects to award a maximum of five discretionary cooperative agreement grants to establish Biospecimen Banks for the National Cancer Institute's Clinical Trials Network.
This funding opportunity uses the U24 research grant mechanism.
The award ceiling for this funding opportunity is $11.75 million.
This funding opportunity is open to institutions/entities that are operating the physical infrastructure of one or more existing Group Banks of human specimens from Phase II and III cancer clinical treatment trials.
A funding opportunity notice from the NIH states: "The goal is to ensure the collection, storage and distribution of well-annotated human bio-specimens, procured from cancer patients participating in NCI [National Cancer Institute]-funded NCTN [NCI National Clinical Trials Network] Phase III and large Phase II clinical treatment trials. The advent of powerful molecular technologies and targeted therapeutics has allowed for development of more effective and in some cases, individualized treatment of cancer patients. Access to specimens with associated high quality clinical, treatment, recurrence and outcome data is critical for developing and validating the tests needed for diagnosis, target identification and prediction of response to therapy. High quality banks of uniformly collected specimens and validated clinical data from patients treated in prospective randomized clinical trials are crucial for supporting cancer research. NCTN Groups organizing and carrying out NCI Phase II-III clinical trials are uniquely positioned to collect and bank bio-specimens from clinical trials. The objective of this FOA [Funding Opportunity Announcement] is to ensure that bio-specimens collected in the course of the NCI-supported cancer clinical trials are available for distribution to interested, qualified members of the scientific community."
The funding opportunity number is RFA-CA-14-501 (CFDA 93.394). The application closing date is Aug. 15.
For more information about Targeted News Service products and services, please contact: Myron Struck, editor, 703/304-1897; email@example.com; http://targetednews.com. To subscribe to our Federal Grant Opportunities Newsletters, contact Dona Harms at: Dona@targetednews.com.